What are the drug interactions between Auvelity (dextromethorphan/bupropion) and Strattera (atomoxetine)?

Drug Interactions Between Auvelity and Strattera

The combination of Auvelity (dextromethorphan/bupropion) and Strattera (atomoxetine) poses a significant pharmacokinetic interaction risk that requires careful monitoring, as bupropion substantially increases atomoxetine exposure by approximately 5-fold through CYP2D6 inhibition, potentially leading to increased cardiovascular effects and other adverse events.

Mechanism of Interaction

The interaction occurs through a well-established metabolic pathway:

• Bupropion is a potent CYP2D6 inhibitor 1. This is actually the intended mechanism within Auvelity itself—bupropion inhibits CYP2D6 to increase dextromethorphan levels.
• Atomoxetine is primarily metabolized by CYP2D6 2. When this pathway is blocked, atomoxetine accumulates significantly.
• Clinical evidence demonstrates a 5.1-fold increase in atomoxetine AUC when co-administered with bupropion, with Cmax rising from 226 to 386 ng/mL 2. This transforms an extensive metabolizer into a functional poor metabolizer.

Clinical Consequences

Cardiovascular Risks (Primary Concern)

Atomoxetine can increase heart rate and blood pressure 3. With 5-fold higher exposure:

• Monitor vital signs closely—check blood pressure and heart rate at baseline, after 1-2 weeks, and regularly thereafter
• Obtain cardiac history before initiating this combination, specifically asking about palpitations, syncope, chest pain, and family history of sudden cardiac death, long QT syndrome, or cardiomyopathy 3
• Consider baseline ECG if any cardiac risk factors are present 3

Serotonin Syndrome Risk

While atomoxetine is not primarily serotonergic, dextromethorphan (in Auvelity) has serotonergic properties:

• Screen for serotonin syndrome symptoms: altered mental status, hypertension, restlessness, myoclonus, hyperthermia, hyperreflexia, diaphoresis, tremor 1
• This risk is particularly relevant if the patient is on other serotonergic agents

Other Adverse Effects

The 5-fold increase in atomoxetine exposure amplifies risks for:

• Gastrointestinal symptoms (nausea, vomiting)
• Somnolence (particularly problematic given that Auvelity itself causes dizziness in 14% of patients 1)
• Decreased appetite and potential growth effects in younger patients 3
• Suicidal ideation (both medications carry this warning 3, 1)

Practical Management Algorithm

If Considering This Combination:

1. Assess necessity: Can one medication be substituted? Extended-release guanfacine or clonidine are alternative ADHD treatments that don't interact via CYP2D6 3.

2. If combination is essential:

   • Start with reduced atomoxetine dosing—consider 25-50% of the typical dose given the 5-fold exposure increase
   • Obtain baseline vital signs and cardiac history 3
   • Screen for other CYP2D6 substrates or inhibitors the patient may be taking 1

3. Monitoring schedule:

   • Week 1-2: Check blood pressure, heart rate, and assess for dizziness, somnolence, GI symptoms
   • Monthly: Vital signs and symptom assessment
   • Ongoing: Watch for mood changes, suicidal ideation, or neuropsychiatric symptoms 1

4. Patient counseling:

   • Warn about fall risk due to dizziness (14% incidence with Auvelity alone 1)
   • Advise caution with driving and operating machinery 1
   • Educate on serotonin syndrome symptoms and when to seek immediate care 1

Critical Caveats

• This interaction is predictable and substantial 2, not theoretical—the 5-fold increase in atomoxetine exposure is clinically significant
• In vitro studies suggesting minimal interaction 4 are contradicted by actual human pharmacokinetic data 2, which should take precedence
• The interaction is competitive and dose-dependent 5, 2—higher doses of either medication increase risk
• Avoid abrupt discontinuation of either medication due to withdrawal risks and potential rebound hypertension (particularly relevant if adding alpha-agonists later 3)

The combination is not contraindicated but requires proactive dose adjustment and vigilant monitoring, particularly for cardiovascular parameters.